# BioTime to Present New OpRegen® Data at American Academy of Ophthalmology Annual Meeting on October 28th

October 22, 2018

**Abstract Selected to be Highlighted by the American Academy of Ophthalmology Organization Committee**

ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 22, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, announced today that updated results from a Phase I/IIa study of its lead product candidate, OpRegen®, a retinal pigment epithelium cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (Dry-AMD), will be presented at the 2018 American Academy of Ophthalmology Annual Meeting (AAO 2018), to be held at the McCormick Place Convention Center in Chicago, Illinois, USA (October 27 – 30, 2018). The abstract presentation, entitled, *"P1/2a Study of Subretinally Transplanted Human Embryonic Stem Cell-Derived RPE Cells in Advanced Dry-Form AMD Patients,"* will be presented as part of the OP02 Retina, Vitreous Original Paper Session on Sunday, October 28th, 2018 between 10:30 AM - 12:30 PM EDT in room S405 by Eyal Banin, MD, PhD, Professor of Ophthalmology, Director, Center for Retinal and Macular Degenerations, Department of Ophthalmology at Hadassah-Hebrew University Medical Center (abstract number PA014). The abstract will provide updated data from patient cohorts 1 through 3 of the study as well as outline initial data from patient cohort 4 and has been selected to be highlighted by the AAO 2018 organization committee.

**About OpRegen®**

OpRegen® is a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry age-related macular degeneration, the leading cause of adult blindness in the developed world. There were no unexpected serious adverse events reported to date. OpRegen® consists of a suspension of retinal pigment epithelial (RPE) cells delivered subretinally as an intraocular injection. RPE cells are essential components of the back lining of the retina and function to help nourish the retina including photoreceptors. OpRegen® has been granted Fast Track designation from the U.S. Food and Drug Administration. OpRegen® is a registered trademark of Cell Cure Neurosciences Ltd., a majority-owned subsidiary of BioTime, Inc.

**About BioTime, Inc.**

BioTime is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. BioTime's pipeline is based on two platform technologies which encompass cell replacement and cell/drug delivery. BioTime's lead cell replacement product candidate is OpRegen®, a retinal pigment epithelium transplant therapy in Phase 2 development for the treatment of dry age-related macular degeneration, the leading cause of blindness in the developed world. BioTime's lead cell delivery clinical program is Renevia ®, an investigational medical device being developed as an alternative for whole adipose tissue transfer procedures. BioTime also has significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. (NYSE American: AST) and OncoCyte Corporation (NYSE American: OCX), and a private company, AgeX Therapeutics, Inc.

BioTime common stock is traded on the NYSE American and TASE under the symbol BTX. For more information, please visit www.biotime.com or connect with the company on Twitter, LinkedIn, Facebook, YouTube, and Google+. To receive ongoing BioTime corporate communications, please click on the following link to join the Company's email alert list: http://news.biotime.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181022005270/en/

Source: BioTime, Inc.

**BioTime, Inc.**
Ioana C. Hone, 510-871-4188
IR@biotimeinc.com